VANTABIOHealthcare Research, Analytics & Technology
Vanta Bioscience Ltd — Profit & Loss Statement
₹15.15
-10.72%
Vanta Bioscience Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Tax Rate For Calcs | 0.30 | 0.02 | 0.30 | 0.30 | — |
| Normalized EBITDA | -4.15 Cr | 1.42 Cr | -0.16 Cr | 4.16 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income From Continuing Operation Net Minority Interest | -4.77 Cr | -2.32 Cr | -6.48 Cr | 0.09 Cr | — |
| Reconciled Depreciation | 4.42 Cr | 4.50 Cr | 2.67 Cr | 1.32 Cr | — |
| Reconciled Cost Of Revenue | 1.33 Cr | 0.72 Cr | 0.99 Cr | 0.77 Cr | — |
| EBITDA | -4.15 Cr | 1.42 Cr | -0.16 Cr | 4.16 Cr | — |
| EBIT | -8.56 Cr | -3.08 Cr | -4.66 Cr | 2.84 Cr | — |
| Net Interest Income | -4.07 Cr | -5.75 Cr | -5.83 Cr | -2.57 Cr | — |
| Interest Expense | 4.07 Cr | 5.75 Cr | 5.61 Cr | 2.61 Cr | — |
| Normalized Income | -4.77 Cr | -2.32 Cr | -6.48 Cr | 0.09 Cr | — |
| Net Income From Continuing And Discontinued Operation | -4.77 Cr | -2.32 Cr | -6.48 Cr | 0.09 Cr | — |
| Total Expenses | 10.64 Cr | 12.91 Cr | 13.17 Cr | 7.54 Cr | — |
| Diluted NI Availto Com Stockholders | -4.77 Cr | -2.32 Cr | -6.48 Cr | 0.09 Cr | — |
| Net Income Common Stockholders | -4.77 Cr | -2.32 Cr | -6.48 Cr | 0.09 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | -4.77 Cr | -2.32 Cr | -6.48 Cr | 0.09 Cr | — |
| Minority Interests | 8.52 Cr | 6.29 Cr | 3.96 Cr | -0.05 Cr | — |
| Net Income Including Noncontrolling Interests | -13.29 Cr | -8.61 Cr | -10.44 Cr | 0.13 Cr | — |
| Net Income Continuous Operations | -13.29 Cr | -8.61 Cr | -10.44 Cr | 0.13 Cr | — |
| Tax Provision | 0.66 Cr | -0.22 Cr | 0.18 Cr | 0.09 Cr | — |
| Pretax Income | -12.63 Cr | -8.83 Cr | -10.26 Cr | 0.23 Cr | — |
| Other Non Operating Income Expenses | 0.11 Cr | 0.11 Cr | 0.62 Cr | 0.33 Cr | — |
| Special Income Charges | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Non Operating Interest Income Expense | -4.07 Cr | -5.75 Cr | -5.83 Cr | -2.57 Cr | — |
| Interest Expense Non Operating | 4.07 Cr | 5.75 Cr | 5.61 Cr | 2.61 Cr | — |
| Operating Income | -8.67 Cr | -3.18 Cr | -6.89 Cr | 2.15 Cr | — |
| Operating Expense | 9.30 Cr | 12.19 Cr | 12.18 Cr | 6.77 Cr | — |
| Other Operating Expenses | 2.82 Cr | 3.90 Cr | 2.13 Cr | 1.84 Cr | — |
| Depreciation And Amortization In Income Statement | 4.42 Cr | 4.50 Cr | 4.50 Cr | 1.32 Cr | — |
| Depreciation Income Statement | 4.42 Cr | 4.50 Cr | 3.38 Cr | 1.32 Cr | — |
| Gross Profit | 0.63 Cr | 9.00 Cr | 5.29 Cr | 8.92 Cr | — |
| Cost Of Revenue | 1.33 Cr | 0.72 Cr | 0.99 Cr | 0.77 Cr | — |
| Total Revenue | 1.96 Cr | 9.72 Cr | 6.28 Cr | 9.69 Cr | — |
| Operating Revenue | 1.96 Cr | 9.72 Cr | 6.28 Cr | 9.69 Cr | — |
| Interest Income | — | 0.06 Cr | 0.06 Cr | 0.08 Cr | 0.00 |
| Rent Expense Supplemental | — | 1.21 Cr | 0.81 Cr | 0.21 Cr | 0.21 Cr |
| Diluted Average Shares | — | 0.63 Cr | 0.63 Cr | 0.63 Cr | 0.63 Cr |
| Basic Average Shares | — | 0.63 Cr | 0.63 Cr | 0.63 Cr | 0.63 Cr |
| Diluted EPS | — | -3.67 | -10.27 | 0.14 | 0.71 |
| Basic EPS | — | -3.67 | -10.27 | 0.14 | 0.71 |
| Other Special Charges | — | -0.04 Cr | — | — | -0.02 Cr |
| Total Other Finance Cost | — | 0.03 Cr | 0.28 Cr | 0.03 Cr | 0.08 Cr |
| Interest Income Non Operating | — | 0.06 Cr | 0.06 Cr | 0.08 Cr | 0.00 |
| Amortization | — | 1.12 Cr | 1.12 Cr | — | — |
| Selling General And Administration | — | 0.49 Cr | 0.77 Cr | 0.27 Cr | 0.27 Cr |
| General And Administrative Expense | — | 0.49 Cr | 0.77 Cr | 0.26 Cr | 0.26 Cr |
| Rent And Landing Fees | — | 1.21 Cr | 0.81 Cr | 0.21 Cr | 0.21 Cr |
| Selling And Marketing Expense | — | — | 0.00 | 31250.00 | 0.01 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Vanta Bioscience Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.